UroGen Pharma (URGN) Debt to Equity (2022 - 2025)
UroGen Pharma's Debt to Equity history spans 4 years, with the latest figure at -$1.16 for Q4 2025.
- For Q4 2025, Debt to Equity rose 91.62% year-over-year to -$1.16; the TTM value through Dec 2025 reached -$1.16, up 91.62%, while the annual FY2025 figure was -$1.16, 91.62% up from the prior year.
- Debt to Equity reached -$1.16 in Q4 2025 per URGN's latest filing, down from -$1.06 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $4.77 in Q3 2024 to a low of -$13.83 in Q4 2024.
- Average Debt to Equity over 4 years is -$1.75, with a median of -$1.24 recorded in 2025.
- The largest YoY upside for Debt to Equity was 554.42% in 2024 against a maximum downside of 815.06% in 2024.
- A 4-year view of Debt to Equity shows it stood at -$1.09 in 2022, then crashed by 38.46% to -$1.51 in 2023, then plummeted by 815.06% to -$13.83 in 2024, then soared by 91.62% to -$1.16 in 2025.
- Per Business Quant, the three most recent readings for URGN's Debt to Equity are -$1.16 (Q4 2025), -$1.06 (Q3 2025), and -$1.31 (Q2 2025).